Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy in preclinical mouse models | Science Translational Medicine
Intravesically delivered engineered bacteria promote PD-1 blockade efficacy in aggressive murine models of bladder cancer.
